Acadia Pharmaceuticals vs PTC Therapeutics
ACAD and PTCT side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ACAD and PTCT compare
PTC Therapeutics is the larger company, worth 1.6 times as much as Acadia Pharmaceuticals ($5.3B against $3.2B).
Acadia Pharmaceuticals grew revenue faster over the last twelve months (14.8% versus −35.1% for PTC Therapeutics).
Acadia Pharmaceuticals keeps more of each dollar of sales as profit, with a net margin of 30.1% compared with −9.2% at PTC Therapeutics.
Acadia Pharmaceuticals scores higher on the StockData Score (17 against 5 for PTC Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ACAD | PTCT |
|---|---|---|
| Size and price | ||
| Market cap | $3.2B | $5.3B |
| Share price | $18.75 | $63.49 |
| Change, 1 year | −22.3% | −15.3% |
| Change, 5 years | −2.1% | 58.7% |
| Beta (5Y) | 0.78 | 1.09 |
| Employees | 798 | 991 |
| StockData Score | ||
| Total score | 17 (better) | 5 |
| Valuation score | 5 (better) | 1 |
| Growth score | 2 (better) | 1 |
| Performance score | 4 (better) | 2 |
| Health score | 6 (better) | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 8.9× | – |
| P/S | 2.7× (better) | 4.6× |
| P/B | 2.3× | – |
| EV/EBITDA | 18.4× | 17.8× (better) |
| P/FCF | 39.4× (better) | 2566× |
| FCF yield | 2.5% (better) | 0.04% |
| Fair value | $31.63 | $48.37 |
| Margin of safety | 40.7% (better) | −31.3% |
| Growth | ||
| Revenue growth (TTM) | 14.8% (better) | −35.1% |
| Revenue growth, 5Y average | 19.4% | 35.4% (better) |
| Net income growth (TTM) | 38.7% (better) | −114% |
| EPS growth (TTM) | 35.5% (better) | −114% |
| Profitability | ||
| Gross margin | 90.5% | – |
| Operating margin | 10.2% | 12.8% (better) |
| Net margin | 30.1% (better) | −9.2% |
| FCF margin | 6.8% (better) | 0.18% |
| Return on equity | 31.4% | – |
| Return on invested capital | 50.8% | – |
| Financial health | ||
| Debt / equity | 0.00 | – |
| Net debt / EBITDA | – | −7.63 |
| Current ratio | 3.82 (better) | 3.27 |
| Altman Z-score | 4.94 (better) | 0.83 |
| Piotroski F-score | 6 (better) | 5 |
| Dividends and buybacks | ||
| Buyback yield | −1.5% | – |
| Shareholder yield | −1.5% | 0.00% (better) |
| Ownership | ||
| Held by institutions | 97.9% | 120% |
| Held by insiders | 27.8% | 3.0% |
| Insider net buying, 12 months | −$2.5M (better) | −$44.2M |
| Short interest, % of float | 6.7% | 9.6% |
Go deeper
- ACAD stock overview
- ACAD income statement
- ACAD valuation and score
- PTCT stock overview
- PTCT income statement
- PTCT valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.